Research
Energy balance
89.5% of participants receiving tirzepatide maintained at least 80% of their weight loss during the lead-in period compared to 16.6% receiving placebo (P < .001).
Tirzepatide significantly improves the likelihood of maintaining weight loss in adults with obesity.
StrongSupportsmedium confidence
Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo (P < .001).
Why this rating
Based on study design from abstract.
Source
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne et al. · JAMA · 2023
rct · n=783Cited 679×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →